Cells is under clinical development by ICamuno Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...
The findings bolster the idea that the inflammasome has a dual role—it promotes inflammation associated with poor outcomes in late cancer stages, but early on, it can help prevent cells from ...